AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 232 min read$MLAB

Crennen Lyndsey Elizabeth sold $40K of MLAB

Crennen Lyndsey Elizabeth (CAO) sold 442 shares of MESA LABORATORIES INC /CO/ (MLAB) at $89.50 on 2026-06-22.

Original reporting
SEC EDGAR · Crennen Lyndsey Elizabeth
Published Jun 23, 2026, 5:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 23, 2026, 5:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MLAB
Neutral
medium confidence
Mentioned
$MLAB
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MLABNeutralLow
01

Why it matters

The newest fact is the CAO’s open-market sale details (442 shares at $89.5020; ~$39.6K total) and post-transaction holdings (2,020 shares).

02

Market read

Traders may note the insider sale as a small sentiment datapoint, but it does not introduce new fundamentals.

03

What to watch

Insider sales are common and often not predictive without accompanying changes in guidance, large-scale selling, or repeated transactions over time.

Relevance 3/10Novelty 5/10Timing: filed 2026-06-23 (after-hours/next session) for a sale dated 2026-06-22

Background

The article is an SEC Form 4 insider transaction disclosure for MESA Laboratories Inc (MLAB).

Company-level read

Ticker impact

$MLABNeutralMedium confidence
Context

Form 4 shows CAO Lyndsey Elizabeth Crennen sold 442 shares of MESA Laboratories at $89.5020 on 2026-06-22, totaling ~$39.6K.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a disclosed insider transaction with modest dollar value and no stated 10b5-1 plan, but it does not include new company fundamentals or guidance.

Market effects

Sector

Minimal; this is company-specific insider activity with no sector-wide catalyst.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale could be for diversification, taxes, or pre-planned personal liquidity needs; absence of a 10b5-1 plan doesn’t necessarily imply bearish expectations.

Key entities

  • issuer
    MLAB

    MESA Laboratories Inc /CO/; subject of the Form 4 insider transaction.

  • insider
    Lyndsey Elizabeth Crennen

    CAO of MESA Laboratories; reported open-market sale of 442 shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MLAB insider trading history →

Related articles

OCT 13
$MLABMedAI 8/10

Mesa Laboratories Announces Restructuring and Savings Plan to Reduce Annualized Costs by Approximately $9.3 Million and Reinvest Approximately $4.3 Million…

MESA LABORATORIES INC /CO/ (MLAB) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Mesa Laboratories Announces Restructuring and Savings Plan to Reduce Annualized Costs by Approximately $9.3 Million and Reinvest Approximately $4.3 Million in Profitable Growth The Restructuring Program focuses Clinical Genomics on profitability and adds resources in

SEC EDGAR 8-K6 min
AUG 17
$MLABMedAI 8/10

Mesa Laboratories (MLAB) Q1 2027 Earnings Call Transcript

Mesa Laboratories (MLAB) reported Q1 FY2027 revenues of $60.1 million, up 1% year over year, with core organic growth of 0.4%. Adjusted operating income was $15.4 million, up 19.5%, and gross margin rose to 64.9%. Net leverage fell to 1.85x after $8.7 million debt repayment. SDC revenue was $24.5 million, down 3.6% organically.

fool.com6 min
AUG 10
$MLABMed

Mesa Labs Announces First Quarter Results

MESA LABORATORIES INC /CO/ (MLAB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Mesa Labs Announces First Quarter Results Lakewood, Colorado , August 10, 2026 – Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or the “Company”), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announc

SEC EDGAR 8-K6 min
MAY 27
$MLABHighAI 9/10

Mesa Labs Announces Fourth Quarter and Fiscal Year 2026 Results

Mesa Laboratories (NASDAQ:MLAB) reported 4Q26 revenues up 2.6% to $63.7M and FY26 revenues up 3.4% to $249.1M. Operating income rose 87% to $2.75M in 4Q26 and 13.3% to $18.5M in FY26. Non-GAAP AOI excluding unusual items increased 49.2% (4Q26) and 11.9% (FY26); FY26 free cash flow was $39.6M, used mainly to repay $14.7M debt, reducing net leverage to 2.11.

manilatimes.net3 min